Marker Therapeutics (MRKR) Assets Average (2011 - 2026)
Marker Therapeutics (MRKR) posted quarterly Assets Average of $18.3 million for Q1 2026, down 6.44% year-over-year from $19.5 million in Q1 2025, and down 10.54% quarter-over-quarter from $20.4 million in Q4 2025.
Marker Therapeutics (MRKR) Assets Average (2011 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Assets Average for 16 consecutive years, with $18.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 6.44% year-over-year to $18.3 million; the TTM figure through Mar 2026 stood at $18.3 million (down 6.44% YoY), while the FY2025 annual figure was $20.5 million, up 4.96% from the prior year.
- Assets Average eased to $18.3 million in Q1 2026 per MRKR's latest filing, from $20.4 million in the prior quarter.
- Across five years, Assets Average topped out at $61.5 million in Q1 2022 and bottomed at $11.3 million in Q3 2024.
- Historically, Assets Average has averaged $26.1 million across 5 years, with a median of $19.5 million in 2025.
- Annual changes were most pronounced in 2023 — Assets Average sank 55.65% — and 2025, when it soared 61.62%.
- Marker Therapeutics' Assets Average stood at $37.8 million in 2022, then slumped by 51.53% to $18.3 million in 2023, then decreased by 10.05% to $16.5 million in 2024, then increased by 23.9% to $20.4 million in 2025, then retreated by 10.54% to $18.3 million in 2026.
- Business Quant data shows MRKR's Assets Average at $18.3 million in Q1 2026, $20.4 million in Q4 2025, and $18.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | 16.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.25 Mn |
| Dec 31, 2025 | 20.40 Mn |
| Sep 30, 2025 | 18.25 Mn |
| Jun 30, 2025 | 15.88 Mn |
| Mar 31, 2025 | 19.51 Mn |
| Dec 31, 2024 | 16.47 Mn |
| Sep 30, 2024 | 11.29 Mn |
| Jun 30, 2024 | 12.88 Mn |
| Mar 31, 2024 | 15.61 Mn |
| Dec 31, 2023 | 18.31 Mn |
| Sep 30, 2023 | 20.72 Mn |
| Jun 30, 2023 | 24.95 Mn |
| Mar 31, 2023 | 31.18 Mn |
| Dec 31, 2022 | 37.77 Mn |
| Sep 30, 2022 | 46.72 Mn |
| Jun 30, 2022 | 53.64 Mn |
| Mar 31, 2022 | 61.55 Mn |
| Dec 31, 2021 | 70.04 Mn |
| Sep 30, 2021 | 76.21 Mn |
| Jun 30, 2021 | 84.42 Mn |